Generalized Pustular Psoriasis
📧 Sign up to get email alerts when something new happens for Generalized Pustular Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Update: A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis [Phase 3]
Phase 3 trial update for TAK-279 in adults with Generalized Pustular Psoriasis or Erythrodermic Psoriasis has completed.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares [Phase 4]
This clinical trial update notes a Phase 4 study evaluating spesolimab for Generalized pustular psoriasis, with status active but not recrui…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study [Phase 2]
A Phase 2 long-term treatment study (Effisayil ON) is evaluating spesolimab in people with generalized pustular psoriasis who participated i…
-
CLINICAL_TRIALS withdrawal · 2026-03-31Clinical Trial Update: Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
Spesolimab post-marketing surveillance study in Korean patients with flares of generalized pustular psoriasis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP [Phase 3]
A Phase 3 study evaluating the long-term safety and efficacy of Imsidolimab (ANB019) in Generalized Pustular Psoriasis was terminated, with …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis [Phase 2]
Clinical trial update for a Phase 2 study of TQH2929 injection in adults with acute flare-ups of generalized pustular psoriasis; the study i…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of Imsidolimab (ANB019) in Generalized Pustular Psoriasis has completed with resul…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Generalized Pustular Psoriasis Registry in Costa Rica
This ClinicalTrials.gov entry documents a Generalized Pustular Psoriasis registry sponsored by Caja Costarricense de Seguro Social in Costa …
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
A completed clinical trial evaluating Legit.Health Plus Support as a diagnostic aid for generalized pustular psoriasis and other skin condit…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
This ClinicalTrials.gov registry study by CorEvitas is collecting real-world safety and effectiveness data on treatments for generalized pus…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis [Phase 3]
Phase 3 study of JNJ-77242113 for generalized pustular psoriasis and erythrodermic psoriasis is active but not recruiting, with results post…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis [Phase 3]
Phase 3 trial update for JNJ-77242113 in generalized pustular psoriasis and erythrodermic psoriasis; status active_not_recruiting with resul…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis [Phase 3]
TAK-279 is being studied in a Phase 3 trial for adults with generalized pustular psoriasis or erythrodermic psoriasis, and the study is curr…
-
FDA approval · 2025-10-21FDA Approved: SPEVIGO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for SPEVIGO (spesolimab-sbzo) from Boehringer Ingelheim Pharmaceuticals, finalizing changes to i…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
A post-marketing surveillance trial evaluating intravenous spesolimab in patients with Generalized Pustular Psoriasis experiencing acute sym…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) [Phase 1]
A Phase 1 clinical study of TQH2929 Injection for generalized pustular psoriasis is currently active but not recruiting. The sponsor is list…
-
CLINICAL_TRIALS trial_result · 2025-06-08Clinical Trial Update: Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
Special-use survey results assess the safety and efficacy of Cosentyx (secukinumab) in pediatric patients with psoriasis vulgaris, psoriatic…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) [Phase 2]
A Phase 2 trial is evaluating the efficacy and safety of HB0034 in patients with generalized pustular psoriasis. The study is currently recr…
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis [Phase 2, Phase 3]
Phase 2/Phase 3 clinical trial evaluating long-term safety and efficacy of HB0034 in generalized pustular psoriasis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options [Phase 3]
Phase 3 expanded-access program in China evaluating Spesolimab for generalized pustular psoriasis in patients with no other treatment option…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options [Phase 3]
Phase 3 expanded-access trial of spesolimab in Japan for flare-ups of generalized pustular psoriasis, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: Biologic Therapy for Generalized Pustular Psoriasis
A clinical trial update reports the completion of a study evaluating a biologic therapy for Generalized Pustular Psoriasis.
-
FDA label_change · 2024-03-18FDA Approved: SPEVIGO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for SPEVIGO (spesolimab-sbzo) to update its labeling following initial approval.
-
CLINICAL_TRIALS trial_result · 2023-12-14Clinical Trial Update: A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis [Phase 2]
A phase 2 trial tested whether BI 655130 (spesolimab) can prevent flare-ups in generalized pustular psoriasis; results have been posted.
-
FDA approval · 2022-09-01FDA Approved: SPEVIGO — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved SPEVIGO (spesolimab-sbzo) from Boehringer Ingelheim in an original application for generalized pustular psoriasis.